About NEC OncoImmunity AS

Robust & reliable neoantigen prediction to empower the next generation cancer immunotherapies.

About NEC OncoImmunity AS

NEC OncoImmunity AS  is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines. The AI technology can be used to identify optimal antigen/epitope targets for infectious disease vaccines, truly personalized cancer vaccines & T cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. 

NEC OncoImmunity AS is a subsidiary of NEC Corporation, and is based in Oslo, Norway.

NEC OncoImmunity AS has assembled a growing and experienced multidisciplinary team of bioinformaticians, software-engineers and data scientists with machine-learning expertise.

  • Richard Stratford Ph.D.
    CEO & Co-Founder
    Richard Stratford Ph.D.
  • Trevor Clancy Ph.D.
    CSO & Co-Founder
    Trevor Clancy Ph.D.
  • Hugues Fontenelle Ph.D.
    General Manager of Development
    Hugues Fontenelle Ph.D.
  • Stig Jarle Pettersen
    CFO
    Stig Jarle Pettersen

Dr. Stratford holds a PhD degree in immunology from Imperial College London. He has more than 12 years of experience in the vaccine industry and more than 16 years of commercial experience in biotechnology. In addtion Dr. Stratford has extensive experience in business development & patent management.

Dr. Clancy has a PhD degree in cancer bioinformatics from the University of Oslo. He has an immunological background developing computational immune-profiling methods, in several national and international cancer related projects. Dr. Clancy has more than 17 years experience in bioinformatics and 12 years of commercial experience in bioinformatics product development. He has an active scientific profile in applying immune informatics for biomarker discovery in cancer.

Dr. Fontenelle has a PhD in Biomedical Engineering from the University of Patras in Greece. Dr. Fontenelle has 16 years experience in biomedical engineering, software development and bioinformatics - with expertise in the development of clinical grade pipelines to analyze NGS data in the field of medical genetics.

Mr Pettersen is a graduate of the Norwegian School of Economics & Business Administration. He is an executive member of the board in Affitech AS. Mr. Pettersen is also on the board of Actigen Ltd. Previously Mr. Pettersen held the position of Chief Financial Officer of Xellia Pharmaceuticals AS and Chief Financial Officer for Cermaq ASA.

A development environment deeply immersed in the combined scientific fields of bioinformatics, biotechnology, onco-immunology and data science

  • Professor Eivind Hovig
    Bioinformatics Advisor
    Professor Eivind Hovig
  • Professor Gustav Gaudernack
    Cancer Immunotherapy
    Professor Gustav Gaudernack
  • Øyvind Grotmol
    Machine Learning Advisor
    Øyvind Grotmol

The research activity of Professor Hovig centers on cancer and bioinformatics. Professor Hovig currently leads both a bioinformatics research team at the Department of informatics, University of Oslo, and a systems biology of melanoma team at the Oslo University Hospital, and he has published more than 160 international peer-review papers. He serves in a number of community roles, including being the scientific lead at the Oslo University Hospital bioinformatics core facility and is tightly integrated with the Norwegian national bioinformatics & genomics efforts, in addition to the bioinformatics activities at the Norwegian Cancer Genome Consortium. Professor Hovig is part of the management group of Elixir Norway. He has also co-founded several Norwegian biotech companies.

Professor Gaudernack was the head of Unit for Cancer Immunotherapy at the Norwegian Radium Hospital from 1995 to 2010, where he initiated an extensive cancer immunotherapy program, including more than 20 clinical studies of cancer vaccines targeting key factors in carcinogenesis and cellular therapy of cancer. His group pioneered vaccines targeting neoantigens (mutant K- and N-ras), starting as early as 1993. Professor Gaudernack has published 200 international peer-reviewed papers and is the co-founder of several cancer immunotherapy companies. He is presently CSO of Ultimovacs AS. He has more than 50 patents and 15 licenses of monoclonal antibodies, cancer vaccines and cancer diagnostics.

Mr Grotmol is the founder, CEO & CTO of Exabel. He has 12 years of experience as a successful tech and AI entrepreneur. He was Director of Research & Innovation at Medallia and VP at Energy Micro, and did extensive AI research as Senior Scientist at Brain Corp.

Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK